[1] Ferlay J, Shin H R, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008[J]. Int J Cancer, 2010, 127(12): 2893-2917. [2] 董秋萍, 蒋湘俐, 张连民,等. 晚期非小细胞肺癌的内科一线及维持治疗[J]. 中国慢性病预防与控制, 2016, 24(4):314-318. [3] Brugger W, Thomas M.EGFR-TKI resistant non-small cell lung cancer(NSCLC): new developments and implications for future treatment [J]. Lung Cancer, 2012, 77(1): 2-8. [4] 陆舜, 纪文翔, 虞永峰. 2014版《NCCN非小细胞肺癌临床实践指南》更新解读[J]. 中国医师进修杂志, 2015, 38(5):318-320. [5] 吴国明. 2012年美国临床肿瘤学会晚期非小细胞肺癌内科治疗新进展[J]. 西部医学, 2012, 24(9):1650-1653. [6] Petrelli F, Borgonovo K, Cabiddu M, et al. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials.[J]. Clin Lung Cancer, 2012, 13(2):107-114. [7] Thongprasert S,Duffied E,Saijo N,et al. Health-Related Quality-of-Life in a Randomized Phase Ⅲ First Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients from Asia with Advanced NSCLC (IPASS) [J]. J Thorac Oncol, 2011, 6(11): 1872-1880. [8] Chen JH, Kuo YH, Luh HP. Optimal policies of non-cross-resistant chemotherapy on Goldie and Coldman's cancer model[J]. Math Biosci, 2013, 245(2):282-298. [9] 林顺欢, 刘淳, 蔡彦敏,等. 化疗交替靶向药物治疗对 EGFR 突变阳性的晚期 NSCLC 患者PFS及 OS的影响[J]. 实用癌症杂志, 2015,30(1):96-98.
2019, Vol. 36 
